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BACKGROUND: Human papillomavirus (HPV) DNA testing can be crucial for women who have limited access to tradi-
tional screening. The current study compared the results obtained through HPV DNA testing with those obtained through
cytology-based screening. METHODS: A total of 3068 women aged 18 to 85 years were enrolled in an opportunistic cervi-
cal cancer screening program developed by the Barretos Cancer Hospital and performed by a team of health professio-
nals working within a mobile unit from March to December 2012, followed by statistical analyses. For each patient, 2
different cervical samples were collected and preserved in a careHPV assay and SurePath medium, respectively. RESULTS:
High-risk HPV (hr-HPV) DNA was detected in 10.0% of women, with the majority (86.7%) demonstrating no abnormal
Papanicolaou test results. The following cytological samples were found to be hr-HPV positive: 8.2% of the normal sam-
ples; 39.4% of the samples with atypical squamous/glandular cells of undetermined significance; 38.5% of the samples
with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion; 55.3% of the sam-
ples with low-grade squamous intraepithelial lesions; and 100% of the samples with high-grade squamous intraepithelial
lesions. Colposcopy examinations were performed among 33.4% of the women with positive results on at least 1 of the
tests (HPV DNA positive and/or cytology with atypical squamous/glandular cells of undetermined significance, cannot
exclude high-grade lesion or high-grade squamous intraepithelial lesions), and 59.5% of these women underwent biopsies.
Among these samples, 18.2% were confirmed as cervical intraepithelial neoplasia. CONCLUSIONS: The careHPV test was
demonstrated to be a feasible alternative to primary screening in low-resource settings accessed through the use of
mobile units. Cancer Cytopathol 2016;000:000–000. VC 2016 American Cancer Society.
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INTRODUCTION
Cervical cancer (CC) is a primary public health problem for women who live in underserved, developing coun-
tries. CC is the third most common disease among women worldwide and the second most common disease in
Brazil, according to the World Health Organization.1,2 Persistent high-risk human papillomavirus (hr-HPV)
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infection is associated with high-grade cervical intraepithe-
lial neoplasia of type 2 or higher (CIN21) and its progres-
sion toward invasive CC.3–6 Molecular tests for HPV
DNA or RNA have been designed to identify hr-HPV in
cervical samples; these tests are both reliable and reproduci-
ble and can be implemented more easily than cytological
analysis.7–14 New guidelines for CC screening recommend
the combined use of HPV testing and cytology over the
use of cytology alone. HPV testing has been shown to
increase the sensitivity of the detection of intraepithelial
lesions in 45% more cases compared with cytological
screening.7–12,15 The detection of hr-HPV cervical infec-
tions is important for determining the prevalence of HPV
in specific populations, thereby aiding in the planning of
appropriate strategies for CC prevention programs.16–18 A
new HPV DNA test approved by the US Food and Drug
Administration (careHPV; Qiagen, Gaithersburg, MD)
has been developed for use in low-income regions. The
careHPV method is a simplified version of the Hybrid
Capture 2 methodology (Digene Corporation, Gaithers-
burg, MD), and is based on antibody binding to magnetic
beads; these beads rapidly capture specific target HPV
nucleic acid sequences that are then detected using a chem-
iluminescent signal.
The careHPV test detects 14 types of hr-HPV (types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
in cervical specimens13,14,19,20 and exhibits high sensitivity
and specificity in the detection of precancerous and cancer-
ous cervical lesions.19,21–24 Populations in many Brazilian
regions have difficulty accessing public health assistance
because many individuals reside in areas that are a distance
from medical care facilities, roads (when they exist) are
extremely bad, and public transportation is lacking. These
conditions represent some of the principle motivations for
the Barretos Cancer Hospital (BCH) to introduce the use
of mobile units (MUs) in 1994 to attend to populations
living in remote rural areas, including the midwest, south-
west, and northern (Amazon) regions of Brazil; women in
these regions comprise a significant percentage of the Bra-
zilian population with HPV-induced lesions. The objective
of the current study was to evaluate the efficiency of the
careHPV test in detecting hr-HPV in women with no pre-
cursor lesions and to evaluate its performance as a primary
screening method in some of the remote Brazilian regions
served by BCHMUs.
MATERIALS AND METHODS
The current study was performed from March to Decem-
ber 2012 using 4 MUs (Fig. 1) from the Cancer Preven-
tion Department of the BCH in S~ao Paulo, Brazil. MUs 2,
3, 4, and 5 were used. Each MU consists of an adapted
truck, with 3 rooms for patient examinations (Papanico-
laou [Pap] testing and prostate and surgical centers), a
reception area, a document cabinet, and a supply room.
The cervical specimens used in this study (careHPV and
cytology tests) were collected in the Pap test room. The
careHPV test was performed in the neighboring room. A
stand was added in this room so that it would be possible
install the careHPV system and perform the HPV test.
HPV DNA analysis was performed in 2 settings: 1) in the
MU while visiting the first 10 cities by one of the authors
(A.T.L.) who was responsible for the research and
Figure 1. Mobile unit design. PAP indicates Papanicolaou. Courtesy of the Engineering Department of Barretos Cancer Hospital.
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molecular analyses (approximately 15% of the samples
were analyzed in the MUs); and 2) at the BCH Molecu-
lar Oncology Center in coordination with the same
individual. The analyses were performed at 2 locations
because space in the MU is limited, and an additional
nurse was required to support patient services and main-
tain the sample collection schedule in the cities. The dis-
ease prevalence results were similar between the 2
laboratory settings.
Study Subjects
A total of 3068 volunteers (all women) were enrolled in an
opportunistic screening program that was regularly performed
in the BCHMUs. The women ranged in age from 18 to 85
years (median, 47 years; standard deviation, 12.4 years). Dur-
ing this period, the MUs visited>50 cities in 4 states, includ-
ing S~ao Paulo,Minas Gerais,MatoGrosso, andGoias.
Ethics and Procedural Overview
All participants who agreed to participate were informed
about the objectives and methods of the study, provided
written informed consent, and answered a structured ques-
tionnaire. The study was previously approved by the BCH
Research Ethics Committee (no. 404/2010). The women’s
privacy was guaranteed.
Preparation and Interpretation of the
Samples
Two samples were collected from each participant, includ-
ing 1 for HPV testing (careHPV) and a second for Pap
testing (SurePath; Becton, Dickinson and Company,
Franklin Lakes, NJ). The samples were properly labeled
and stored at 4 to 88C or at -208C when the test was not
performed within 7 days.
careHPV Test
The careHPV rapid HPV-DNA detection method
involves specific target HPV nucleic acid sequences that are
rapidly bound by antibodies attached to magnetic beads
and then detected through chemiluminescence. The ratio
between relative light units and a cutoff is calculated by the
careHPV system, and samples are considered positive for
hr-HPV when this ratio is >1.0. This method can detect
14 types of hr-HPV (types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, and 68), and >90 specimens can be
processed within 2.5 hours.12,13,19
Pap Test
Specimens were collected for liquid-based cytology using
SurePath medium by the same well-trained professional
who collected the careHPV samples. The samples were
obtained using a Rovers Cervex-Brush equipped with a
removable brush head (Rovers Medical Devices, Oss, the
Netherlands). Ectocervical and endocervical canal samples
were immediately placed in SurePath medium. Specimens
were subsequently forwarded to the Department of
Pathology at BCH for preparation, analysis, and classifica-
tion using the BD FocalPoint Slide Profiler (TriPath
Imaging, Burlington, NC) for the first triage step. The
specimens were first screened by cytotechnicians using an
automated microscope, and all abnormal cases were
rescreened by a senior cytopathologist.
Follow-Up
The study proceeded according to the results of HPV and
cytology testing. If the cytological test classified the sample
as normal or atypical squamous/glandular cells of undeter-
mined significance (ASC/AGC-US) and the hr-HPV test
was negative, the participants received a letter including
their laboratory results without any follow-up recommenda-
tions, and were advised to follow only periodic screening
adherence. If the hr-HPV test was positive and/or the abnor-
mal cytology was classified as atypical squamous/glandular
cells of undetermined significance, cannot exclude high-
grade lesion (ASC/AGC-H) or high-grade squamous intrae-
pithelial lesion (HSIL), the participants were referred to the
hospital for colposcopy and/or biopsy, if necessary.
Statistical Analysis
Statistical analysis was performed using SPSS statistical
software (version 20.1; IBM Corporation, Armonk, NY)
and MedCalc statistical software (version 11.1; MedCalc,
Ostend, Belgium). Chi-square tests were used to compare
frequencies among groups and the Fisher exact test was
used when the chi-square test was insufficient. The Student
t test was performed to compare means between groups. P
values <.05 were considered statistically significant. A
screening criterion was statistically analyzed considering
only those women with a positive hr-HPV test.
RESULTS
At baseline, a total of 3068 women with a median age of
47 years (range, 18-85 years) participated in the current
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study. Among the participants, 2476 women (80.7%)
were aged >35 years. The mean ages of the HPV-negative
and HPV-positive women were 46.9 years and 41.0 years,
respectively (P <.0001). hr-HPV DNA was detected in
10.0% of the samples (307 of 3068 samples). Among the
participants, 95.4% (2927 of 3068 participants) had at
least 1 previous Pap test result, and 58.6% reported having
had only 1 sexual partner in their lifetime. The demo-
graphic and histocytopathological characteristics of the par-
ticipants are shown in Table 1. The results achieved based
on the cytology, colposcopy, and biopsy findings for the
women who were tested for HPV DNA are presented in
Table 2.
Approximately 91.8% of the women (2696 women)
who were classified as exhibiting normal cytology (negative
for intraepithelial lesion or malignancy) were HPV nega-
tive. Similarly, 39.4% of the women (26 of 66 women)
diagnosed with ASC/AGC-US, 38.5% of the women (5 of
13 women) diagnosed with ASC/AGC-H, and 55.3% of
the women (21 of 38 women) diagnosed with low-grade
intraepithelial lesion (LSIL) were also found to be HPV
positive. Women aged <34 years exhibited elevated hr-
HPV prevalence; this prevalence was found to be lower in
women aged 35 to 44 years and was higher in women aged
>45 years. Women who were positive for hr-HPV with
cytological abnormalities (ASC/AGC-H, LSIL, or HSIL)
were referred to BCH for colposcopy and biopsy. The
careHPV test was positive for all 15 women who were
diagnosed with HSIL on cytology. However, of these 15
cases, 8 women underwent to colposcopy and biopsy, of
which, 3 women were diagnosed with invasive carcinoma,
1 woman with CIN3, 2 women with CIN2 and 2 women
with CIN1. If the participants were unable to travel to
BCH, they were advised to present for examination at the
hospital closest to where they lived.
Molecular Test Performance
According to the previously described criteria, 10.8% of
the women (332 of 3068 women) were referred for follow-
up and 33.4% of these women (111 women) underwent
colposcopy examinations (1 woman was excluded from
this analysis due to death from another cause). Among the
women who underwent colposcopies, 92.8% (103 of 111
women) were infected with hr-HPV, 43.2% (48 of 111
women) were diagnosed with CIN21, and 32.4% (36
of 111 women) were classified as having unsatisfactory
findings because the transformation zone or the endocervi-
cal borders of the lesion were not identified during the
examination.25
Based on these results, the HPV DNA test demon-
strated accuracy, with a sensitivity of 100% (95% confi-
dence interval, 75.3%-100%) and a specificity of 10.8%
(95% confidence interval, 5.1%-19.6%), considering the
cervical biopsy as the gold standard. However, if biopsy
was not performed, colposcopy was considered the gold
standard (59.4% of the women referred for follow-up [66
of 111 women] did not undergo the procedure). Conse-
quently, women with normal findings or findings that
were suggestive of low-grade intraepithelial lesions during
colposcopy were categorized as disease free. When the col-
poscopy examination suggested a high-grade intraepithelial
lesion (even without biopsy), the women were classified as
being positive for HPV-induced disease.
DISCUSSION
All the severe cervical lesions confirmed by biopsy were
found to be positive for hr-HPV. Moreover, the careHPV
test was easy to perform, and we confirmed previous
reports indicating that careHPV is easily used in screening
settings.12–14 The careHPV method was primarily
designed for use in remote areas in which human resources
and laboratory facilities are scarce,13,14 which spurred us to
evaluate the implementation of an “easy-to-perform”
molecular HPV test for CC screening in underserved areas,
because high sensitivity is critical for identifying women
with cervical lesions. Carefully designed strategies and effi-
cient screening programs are needed to identify those
women at risk of developing cancer because access to hos-
pitals and ambulatory clinics is poor due to the long dis-
tances involved and the precariousness of Brazilian roads.
The MUs from the BCH are able to visit remote areas in
the midwest, southwest, and northern (Amazon) regions of
Brazil, accommodating approximately 24,000 visits in 157
cities in 2013, thus serving the needs of a significant per-
centage of women with HPV-induced tumors. The ability
to identify women with cervical lesions and provide an
appropriate medical referral is critical for saving lives and
reducing mortality due to CC.
Based on the results of the current study, the preva-
lence of hr-HPV was 10.0% (307 of 3068 women) among
women with a median age of 47 years. The results of the
current study are consistent with those of other studies
regarding HPV detection in Brazilian women. de Aguiar
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et al,25 Lorenzi et al,19 Rosa et al,26 and Nonnenmacher
et al27 reported HPV prevalence rates of 10.5%, 12.3%,
12.3%, and 15%, respectively. The majority of these
women lived in rural or remote areas of Brazil and experi-
enced difficulties in accessing medical care or the heath
assistance infrastructure. These women lived in resource-
poor settings, and the majority had poor literacy, thereby
hindering their access to information regarding the role of
HPV infection in the development of CC.
The prevalence of HPV in women with normal
cytology ranges from 10.0% to 24.5%.3,28,29 In the cur-
rent study, we reported a slightly lower prevalence (8.2%)
(Table 2). However, in women aged <34 years with nor-
mal cytology, the prevalence of hr-HPV was found to be
higher. The majority of women with high-grade lesions
(CIN31) were aged 25 to 44 years; similar results were
reported in other studies.3,27,29–32 The prevalence of hr-
HPV was found to be lower in women aged 35 to 44
years, except for those women with specimens classified as
negative for intraepithelial lesion or malignancy and ASC-
US, among whom the prevalence decreased and remained
stable or continuously decreased with age, a finding that is
consistent with other reports.3,29,30 HPV tests based on the
detection of HPV DNA or RNA are considered more effi-
cient than cytological analysis for the screening of under-
served populations, due to the simplicity of the automated
methodology and the reproducibility of the results, which
are advantages that are not obtained using operator-
dependent cytology.13,14,33,34 A recent study comparing
careHPV and the Pap test35 described these tests as having
equal performance in the detection of CIN21 and
CIN31 and these findings were not dependent on the age
of the women. In addition, other studies have described
the careHPV test as having acceptable cost-effectiveness
when compared with Hybrid Capture 2, the OncoE6 cer-
vical test (Arbor Vita Corporation, Fremont, Calif), and
Liquid-Based Cytology (LBC), thereby recommending it
TABLE 2. Frequency Comparison Between Cyto-
logical Results, Colposcopy, and Biopsy According
to HPV Testinga
Negative HPV
DNA, No. (%)
Positive HPV
DNA, No. (%)
Cytology
No atypia 2696 (91.8) 240 (8.2)
ASC/AGC-US 40 (60.6) 26 (39.4)
ASC/AGC-H 8 (61.5) 5 (38.5)
LSIL 17 (44.7) 21 (55.3)
HSIL 0 (0.0) 15 (100.0)
Colposcopy
Normal 1 (3.7) 26 (96.3)
Suggestive of low-grade
intraepithelial lesion
4 (10.0) 36 (90.0)
Suggestive of high-grade
intraepithelial lesion
0 (0.0) 8 (100.0)
Unsatisfactory 3 (8.3) 33 (91.7)
Biopsy
Normal 6 (22.2) 21 (77.8)
CIN1 1 (3.7) 26 (96.3)
CIN2 0 (0.0) 5 (100.0)
CIN3 0 (0.0) 4 (100.0)
Invasive carcinoma 0 (0.0) 3 (100.0)
Abbreviations: ASC/AGC-H, atypical squamous/glandular cells of undeter-
mined significance, cannot exclude high-grade lesion; ASC/AGC-US, atypi-
cal squamous/glandular cells of undetermined significance; CIN, cervical
intraepithelial neoplasia (types 1, 2, and 3); HPV, human papillomavirus;
HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squa-
mous intraepithelial lesion.
a Exact Fisher test P value of .05 for statistical significance. (p<.001).
TABLE 1. Characteristics of the Study Population
Characteristica Frequency, No. (%)
Previous Pap test 3059
Yes 2927 (95.7)
No 132 (4.3)
Tobacco use 3064
No 2638 (86.1)
Yes 426 (13.9)
Oral contraceptive use 3060
No 2515 (82.2)
Yes 545 (17.8)
Parity 3063
0 252 (8.2)
1–3 2055 (67.1)
4–6 596 (19.5)
>6 160 (5.2)
No. of sexual partners 3034
1 1779 (58.6)
>1 1255 (41.4)
Cytology 3068
No atypia 2936 (95.7)
ASC/AGC-US 66 (2.2)
ASC/AGC-H 13 (0.4)
LSIL 38 (1.2)
HSIL 15 (0.5)
Colposcopy 111
Normal 27 (24.3)
Suggestive of low-grade
intraepithelial lesion
40 (36.0)
Suggestive of high-grade
intraepithelial lesion
8 (7.2)
Unsatisfactory 36 (32.4)
Biopsy 66
Normal/Chronic cervicitis 27 (40.9)
CIN1 27 (40.9)
CIN2 5 (7.6)
CIN3 4 (6.1)
Invasive carcinoma 3 (4.5)
Abbreviations: ASC/AGC-H, atypical squamous/glandular cells of undeter-
mined significance, cannot exclude high-grade lesion; ASC/AGC-US, atypi-
cal squamous/glandular cells of undetermined significance; CIN, cervical
intraepithelial neoplasia (types 1, 2, and 3); HSIL, high-grade squamous
intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; Pap,
Papanicolaou.
a Data were excluded from the analysis when not informative.
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as an option in primary screening, especially in low-
income settings.21,22,35 The findings of the current study
endorse this premise because the careHPV test recognized
high-grade intraepithelial lesions (CIN31). The perform-
ance indices confirm the hypothesis, with remarkably high
sensitivity and negative predictive values obtained for the
results of the HPV test, either alone or in association with
cytology and visual inspection. However, the specificity
was lowest, which could be explained by the presence of
HPV not necessarily being associated with the existence of
a high-grade lesion36 or also by the fact that the women
who were negative for both tests (molecular and cytology)
were not evaluated. Optionally, reflex cytology can be used
when HPV testing provides a positive result.37 The accu-
racy of careHPV as calculated from the area under the
receiver operating characteristic curve demonstrated that
despite the low specificity, careHPV could be considered
in the detection of hr-HPV and CIN21, as proposed.
ASC-US is a common diagnosis in CC screening and
is reportedly found in 2% to 5% of screened women.38,39
This result represents an uncertain alteration that generally
ranges from normal to LSIL. HPV testing has frequently
been used to assess women who have been diagnosed with
ASC-US in an attempt to refer for colposcopy only those
women who are positive for hr-HPV.38,39
In the current study, we found that 40.0% of the
women with a cytological assessment of ASC/AGC-US
(26 women) were positive for hr-HPV; all of these women
were referred for colposcopy, but only approximately one-
half underwent the procedure. This cytological result was
higher than the values obtained in other Brazilian studies
conducted in Porto Alegre (southern region),40 Belem
(northern region),41 Natal (northeast region),30 and Pelotas
(southern region).42 Among the women who underwent
colposcopic examination, 24.3% (27 of 111 women) were
diagnosed with normal findings; 36.0% (40 of 111
women) received a diagnosis consistent with a low-grade
intraepithelial lesion; 7.2% (8 of 111 women) had a diag-
nosis consistent with a high-grade intraepithelial lesion;
and 32.4% (36 of 111 women) received unsatisfactory
diagnoses.
Some guidelines recommend follow-up for women
with cytological findings of ASC-US and a negative hr-
HPV test.9,38 In the current study, women with cytological
findings of ASC-US and a negative hr-HPV test were not
referred for colposcopy. HPV testing has been indicated
for the screening of women at risk of developing cervical
lesions due to its higher sensitivity, lower subjectivity, and
greater reproducibility compared with cytology. Thus,
HPV testing may improve the prevention of cervical pre-
cursor lesions to a greater extent than cytology.13,36,43,44
All of the HSILs observed using cytology were found to be
positive for hr-HPV. Among the identified LSILs, 55.3%
were positive for hr-HPV. This result is comparable to
those found in other studies.30,40 One of the limitations of
the current study was that the group in whom both pri-
mary tests (cytology and molecular tests) yielded negative
results, representing 89.1% of all women enrolled (2736 of
3068 women), was not referred for colposcopy or biopsy.
If a bias verification method were to be applied to the data
from the current study, the sensitivity might decrease and
the specificity might increase. A Canadian study recorded a
rate of CIN21 of 0.61% when cytology and HPV test
results were both negative.37 Among the women referred
for colposcopy, 66.6% (221 women) did not undergo this
examination. On average, the women waited 166.7 days
(median, 156.0 days; standard deviation, 69.0 days) for
colposcopy examination (range, 3-407 days). A recent
study45 demonstrated that >46% of cases are examined
within 180 days after referral and that the majority of inva-
sive cancers are treated after 180 days. The authors con-
cluded that the diagnosis did not differ depending on
whether colposcopy was conducted before the positive test
or 6 months after it. When a colposcopy is performed ear-
lier, patient anxiety is lower, and follow-up losses can be
reduced. Furthermore, invasive lesions that are missed by
cytology might be identified. The detection of hr-HPV
DNA is important for women with an uncertain cytologi-
cal diagnosis who require a precise result to be referred
for colposcopy or to be followed after treatment of a
high-grade lesion. Colposcopy examinations are limited in
the public health care systems of developing countries for
several reasons, including a lack of expert professionals or
equipment and suboptimal preservation of equipment.
This situation affects the interval between referral and col-
poscopy and the confirmation of lesions by biopsy. Treat-
ment is consequently postponed to ameliorate patient
anxiety and fear.45–47 Fakokunde et al48 observed that
women who underwent colposcopies after 6 months exhib-
ited less of a tendency to obtain treatment or to develop
high-grade lesions compared with a group of women who
were examined earlier. The time that elapses between cyto-
logical sampling and colposcopy examination varies; how-
ever, Pap tests for high-grade lesions are given high
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priority. The majority of HPV infections clear spontane-
ously, and only those infections involving high-risk HPV
persist. Because progression toward a malignant lesion
takes a relatively long time, an opportunity exists to iden-
tify and adequately treat patients with premalignant cervi-
cal lesions.46 The results of the current study have
demonstrated that using cytology and HPV testing in
combination improves the specificity of the results, thereby
enhancing the probability of detecting severe HPV-
induced cervical lesions. These results also demonstrated
that the careHPV test is accurate for primary screening in
rural and remote areas. If performed within MUs, the
careHPV test has the potential to improve the detection of
cervical precursor lesions in underserved settings.13,49,50
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